Table 2. Overview of the alterations affecting T-LBL samples.
| Sample code | FAS mutation | FAS expression | FASLG expression | FADD expression | CASP8 expression | CASP3 expression |
|---|---|---|---|---|---|---|
| 000–220 | + | ↓ | nd | nd | nd | nd |
| 00800-SD1–1 | + | ↓ | nd | nd | nd | nd |
| 02M-121 | + | ↓ | nd | nd | nd | nd |
| 20040731 | — | ↓ | — | ↓ | ↓ | ↓ |
| 20050094 | — | ↓ | — | ↓ | ↓ | ↓ |
| 20040730 | + | ↓ | — | — | — | — |
| 20041008 | — | ↓ | — | — | — | — |
| 20040734 | — | ↓ | — | — | ↓ | ↓ |
| 20030516 | — | — | — | ↓ | ↓ | ↓ |
| 20032268 | — | — | — | — | — | — |
| 07010829 | — | — | — | — | — | — |
| 05010346 | — | — | — | — | — | — |
| 01030188 | — | — | — | ↓ | — | — |
| 02070238 | — | — | — | ↓ | — | — |
| 02050408 | — | — | — | — | — | — |
| 04011685 | + | ↓ | — | ↓ | ↓ | ↓ |
| 04010460 | — | — | — | — | — | — |
| 04010153 | — | — | — | — | — | — |
| 11010521 | — | — | — | — | — | — |
| 07010226 | — | — | — | — | — | — |
| 01030192 | — | — | — | — | — | — |
| 04010038 | — | ↓ | ↑ | — | — | — |
| 46090749 | — | — | — | — | — | — |
| 04100080 | — | — | — | ↓ | — | — |
| 04090135 | — | — | — | ↓ | — | — |
| 04030154 | — | — | — | — | — | — |
| Total | 5/26 (19.2%) | 10/26 (38.5%) | 1/23 (4.3%) | 8/23 (34.8%) | 5/23 (21.7%) | 5/23 (21.7%) |
Summary of the results obtained in our T−LBL sample series, concerning mutations affecting FAS, alterations of FAS expression and alterations of other members of the Fas/FasL pathway. T-LBL cases with any of the elements altered are in bold. The percentage of each alteration type is also indicated. (+), mutation. (−), normal situation. Arrows denote altered expression. nd, not determined